Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego Ripamonti

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Evidence-Based Medicine|August 28, 2016
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infectionDiego Ripamonti
AIDS (London, England)|February 10, 2018
Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studiesDiego Ripamonti, Maurizio Zazzi
The New England Journal of Medicine|October 30, 2014
Brain abscessMarco Rizzi, Diego Ripamonti
Current Opinion in Investigational Drugs (London, England : 2000)|July 31, 2008
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infectionDiego Ripamonti, Franco Maggiolo
The Lancet. HIV|September 15, 2023
Emergent HIV drug resistance in non-inferiority trialsDiego Ripamonti, Maurizio Zazzi
Journal of Acquired Immune Deficiency Syndromes (1999)|April 4, 2014
Do lopinavir and ritonavir require a dose adjustment during pregnancy?Diego Ripamonti, Dario Cattaneo
Frontiers in Public Health|September 30, 2024
Editorial: World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIVDiego Ripamonti, Segundo R Leon
Lancet (London, England)|April 28, 2004
HIV-1 and hepatitis B virus: time for a re-think?Diego Ripamonti, Franco Maggiolo, Fredy Suter
The Journal of Antimicrobial Chemotherapy|April 26, 2005
Switch strategies in patients on effective HAARTFranco Maggiolo, Diego Ripamonti, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Evidence-Based Medicine|August 28, 2016
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infectionDiego Ripamonti
AIDS (London, England)|February 10, 2018
Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studiesDiego Ripamonti, Maurizio Zazzi
The New England Journal of Medicine|October 30, 2014
Brain abscessMarco Rizzi, Diego Ripamonti
Current Opinion in Investigational Drugs (London, England : 2000)|July 31, 2008
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infectionDiego Ripamonti, Franco Maggiolo
The Lancet. HIV|September 15, 2023
Emergent HIV drug resistance in non-inferiority trialsDiego Ripamonti, Maurizio Zazzi
Journal of Acquired Immune Deficiency Syndromes (1999)|April 4, 2014
Do lopinavir and ritonavir require a dose adjustment during pregnancy?Diego Ripamonti, Dario Cattaneo
Frontiers in Public Health|September 30, 2024
Editorial: World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIVDiego Ripamonti, Segundo R Leon
Lancet (London, England)|April 28, 2004
HIV-1 and hepatitis B virus: time for a re-think?Diego Ripamonti, Franco Maggiolo, Fredy Suter
The Journal of Antimicrobial Chemotherapy|April 26, 2005
Switch strategies in patients on effective HAARTFranco Maggiolo, Diego Ripamonti, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
Pageof 8